Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

751

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Amivantamab
DRUG: Amivantamab
DRUG: Lazertinib
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Janssen Research & Development, LLC